Compare Gilead Sciences, Inc. (GILD) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Wheaton Precious Metals Corp — how do they compare? Gilead Sciences, Inc. trades at $135.88 (market cap $168.35B), while Wheaton Precious Metals Corp trades at $135.37 (market cap $60.94B). The key difference: Gilead Sciences, Inc. is far larger — about 2.8× Wheaton Precious Metals Corp's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | WPM | |
|---|---|---|
Market Cap | $168.35B | $60.94B |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $165.72 |
52-Week Low | $110.56 | $91.02 |
Enterprise Value | $191.42B | $62.82B |
Dividend Yield | 2.42% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
Wheaton Precious Metals (WPM) trades at $135.51, up 1.59% on the day, reflecting strong momentum amid record financial performance. The stock exhibits a bullish technical trend, supported by consecutive earnings beats and robust cash flow growth. Recent results highlight significant revenue and profit expansion, driven by higher metal prices and increased sales volumes. Analyst sentiment remains overwhelmingly positive, with a consensus Buy rating and a price target implying substantial upside potential.
The outlook for WPM is favorable, underpinned by its high-margin streaming model and exposure to rising precious metal prices. Key opportunities include sustained earnings growth and strategic deal capacity, while risks involve commodity price volatility and execution of future streaming agreements. The stock's current valuation multiples suggest premium pricing, requiring continued operational excellence to justify further appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
